19.61
Amphastar Pharmaceuticals Inc stock is traded at $19.61, with a volume of 313.78K.
It is down -0.15% in the last 24 hours and down -0.66% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$19.64
Open:
$19.48
24h Volume:
313.78K
Relative Volume:
0.52
Market Cap:
$864.66M
Revenue:
$720.53M
Net Income/Loss:
$79.23M
P/E Ratio:
11.78
EPS:
1.6648
Net Cash Flow:
$132.94M
1W Performance:
-5.31%
1M Performance:
-0.66%
6M Performance:
-29.00%
1Y Performance:
-15.47%
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals Inc
|
19.61 | 889.80M | 720.53M | 79.23M | 132.94M | 1.6648 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Crude Oil Gains 2%; Comcast Shares Spike Higher - Benzinga
Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside - TradingView
AMPH Downgraded by B of A Securities -- Price Target Lowered to $20 - GuruFocus
BofA cuts Amphastar stock rating on limited growth visibility By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – LS:A11664 - TradingView
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index - marketscreener.com
Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – GETTEX:29A - TradingView
Price to book forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView
Price to sales forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH - TradingView
Price to earnings forward of Amphastar Pharmaceuticals, Inc. – LS:A11664 - TradingView
Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH) - TradingView
AMPH Forecast — Price Target — Prediction for 2027 - TradingView
Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment - Clinical Pain Advisor
Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AMPH Technical Analysis & Stock Price Forecast - Intellectia AI
Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amphastar Pharmaceuticals Inc - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar - Tech Times
Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Challenging QuarterFull Year Guidance - newsline.com
(AMPH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Healthcare Stock Picks: RadNet and Amphastar to Sell, One Stock to Watch | June 2026News and Statistics - IndexBox
Amphastar Pharmaceuticals pivots to proprietary drugs, biosimilars for growth - MSN
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth - MarketBeat
How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts - Yahoo Finance
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged - GlobeNewswire
Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag - MSN
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag - MarketBeat
Amphastar (AMPH) director awarded RSUs and options with tax withholding update - Stock Titan
Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan
Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan
Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-pay - Stock Titan
Amphastar Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ZASLOFF MICHAEL Amoomoo - Moomoo
(AMPH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty - Yahoo Finance
Amphastar (AMPH) Q1 2026 Earnings Transcript - AOL.com
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):